CTOR Citius Oncology, Inc.

2

Health Care [ 12/12 ] | Life Sciences Tools & Services [ 71/74 ]

NASDAQ | Common Stock

Price
$0.98
Decreased by -1.42%
Dollar volume (20D)
95.48 K
ADR%
11.11
Shares float
0.00
Shares short
39.42 K [N/A%]
Shares outstanding
2.00 M
Market cap
N/A
Beta
N/A
Price/earnings
N/A
20D range
0.95 1.45
50D range
0.93 1.91
200D range
1.88 4.42

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies.

It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma.

The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY